ArticleFrontiers in immunology2025
Gut microbiota alterations and systemic inflammation in community-acquired pneumonia: a prospective gut-lung axis study.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The gut-lung axis and viral pneumonia: Unrevealing the gut microbiota.Pharmaceutical science advances · 2026Review
- Microbiota-Immune Crosstalk in Pneumonia and Acute Lung Injury: Mechanisms, Evidence, and Therapeutic Opportunities.Microorganisms · 2026Review
- Metabolomic signatures of early pathway disruptions and clinical outcomes in community-acquired pneumonia: a prospective case-control study.BMC pulmonary medicine · 2026Article
- Insights into the mechanism of intestinal flora imbalance and immune disorder in co-morbidity of pneumonia and diarrhea in children.Frontiers in pediatrics · 2026Review
- Gut microbiota dysbiosis in infants and young children with severe pneumonia and sepsis: a matched case-control study identifying potential biomarkers for early risk stratification.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Up to now, only a few scattered studies have provided some evidence for the relationship between gut microbiota and community-acquired pneumonia (CAP), and the mechanisms by which gut microbiota contributes to the occurrence and development of CAP via the gut-lung axis require further investigation. In this study, fecal and serum samples from CAP patients and healthy controls were analyzed using 16S rRNA gene sequencing and enzyme-linked immunosorbent assay. The results showed that compared with healthy controls, alpha-diversity of gut microbiota in CAP patients was significantly reduced, and beta-diversity was significantly different at operational taxonomic units (OTUs), class, order, family, genus, and species levels. The abundance of short-chain fatty acid-producing genera in CAP patients decreased significantly, such as Blautia and Agathobacter. Meanwhile genera including Gemmiger, Enterocloster, and Thomasclavelia were enriched in the CAP. Functional predictions based on KEGG Orthologies suggested that the gut microbiota of CAP patients was enriched in pathways related to carbohydrate metabolism and bacterial infection. Serum detection revealed that the levels of lipopolysaccharide (LPS), TNF-α, and IL-6 were significantly increased in CAP patients. Our findings suggest that gut microbiota dysbiosis in CAP patients is associated with increased translocation of LPS into the bloodstream and activation of systemic inflammation, indicating that the gut-lung axis may play a potential role in the pathogenesis of CAP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.